CareDx Inc. (CDNA)
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
CareDx NASDAQ: CDNA executives outlined the company's growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration.
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing
CDNA unveils AlloSeq Nano, delivering high-resolution HLA typing in under 3 hours, aiming to boost transplant diagnostics speed and lab efficiency.
All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA
Bamco Inc. NY grew its stake in shares of CareDx, Inc. (NASDAQ: CDNA) by 29.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,155,180 shares of the company's stock after buying an additional 719,523 shares during the period. Bamco
CareDx Introduces VANTx AI Platform for Complex Transplant Datasets
CDNA launches VANTx, an AI-driven cloud platform that turns complex transplant datasets into insights to support clinical research and real-world evidence.
